Key Highlights
- Fourth quarter revenue reached $9.81 billion, surpassing analyst projections of $9.63 billion.
- Adjusted earnings per share of $1.55 exceeded the Street consensus of $1.54.
- Cardiovascular division revenue climbed 13.8% to $3.8 billion, with Cardiac Ablation Solutions soaring 78% worldwide.
- Fiscal 2027 adjusted EPS outlook of $5.90–$6.00 fell short of analyst expectations of $6.06; tariff-related costs projected at approximately $300 million.
- Quarterly dividend increased to $0.72, marking the company’s 49th consecutive annual dividend hike ($2.88 annualized).
Medtronic delivered its most robust full-year revenue expansion in ten years, propelled by exceptional demand for cardiac treatment devices. Fourth quarter sales totaled $9.81 billion, eclipsing Wall Street’s $9.63 billion projection, while adjusted earnings per share of $1.55 narrowly beat the $1.54 consensus figure. The company’s full-year organic revenue expansion of 5.8% represents its strongest annual showing since 2015.
While the top-line figures impressed investors, certain underlying elements raised concerns — particularly the fiscal 2027 EPS guidance band of $5.90 to $6.00, which missed the $6.06 target that Wall Street analysts had anticipated.
Trade tariff expenses represent a tangible financial burden. Management anticipates approximately $300 million in tariff-related costs during fiscal 2027, a substantial increase from the roughly $185 million impact recorded in fiscal 2026. Company leadership has been transparent about this growing expense.
Cardiovascular Division Powers Performance
The cardiovascular business unit emerged as the primary growth catalyst this quarter. Revenue surged 13.8% to $3.8 billion — representing nearly 40% of consolidated company sales. Cardiac Ablation Solutions experienced remarkable 78% worldwide growth, including explosive 124% expansion in the United States market, capturing an additional 8 percentage points of market share.
Pulsed field ablation technology and transcatheter aortic valve replacement procedures represent the two treatment modalities experiencing the steepest adoption trajectories currently, and Medtronic has established substantial competitive positioning in both categories.
The Micra leadless pacemaker system delivered mid-teen percentage growth, while the OmniaSecure defibrillation lead enjoyed a successful domestic market introduction.
Neuroscience division revenue increased 5% to $2.75 billion, marginally below the $2.76 billion analyst projection. Medical Surgical sales reached $2.39 billion, representing 8% reported growth and 5.1% organic expansion, with the Acute Care & Monitoring category achieving low double-digit percentage gains.
Diabetes segment revenue climbed 15% on a reported basis to $837 million, and this business unit will remain integrated within Medtronic throughout the entire twelve-month fiscal 2027 guidance period.
Strategic Acquisitions and Product Development
Medtronic has pursued an aggressive bolt-on acquisition strategy following the separation of its diabetes division. Throughout the quarter and full fiscal year, the company closed the CathWorks transaction, revealed intentions to acquire Scientia Vascular and SPR Therapeutics (for approximately $650 million combined), and submitted regulatory documentation to the FDA seeking approval for its Hugo robotic-assisted surgery platform for general surgery and gynecologic procedures.
The Hugo regulatory submission represents a critical milestone in the company’s surgical robotics strategy — a competitive arena where Medtronic has been methodically building capabilities without fanfare.
The medical device manufacturer also boosted its quarterly dividend distribution to $0.72 per share, extending its streak of consecutive annual dividend increases to 49 years.
Looking ahead to fiscal 2027, Medtronic projects organic revenue growth between 6.75% and 7.25%. Full-year fiscal 2026 revenue totaled $36.4 billion, reflecting 8.4% reported growth and 5.8% organic expansion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
